Skip to content
DataLookout
Menu

NCT07940738

Ph 1 Study Long-acting Interleukin-7, Efineptakin Alfa, to Enhance Immune Reconstitution After PTCy

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Recommended phase II dose (RP2D)
Timeframe: Up to 90 days
Absolute Lymphocyte Count Recovery
Timeframe: Up to 90 days

Secondary (1)

Occurrence of infections

Arms and interventions

Efineptakin Alfa (rhIL-7-hyFc)Experimental

Participants will receive a single intramuscular dose of efineptakin alfa (NT-I7, rhIL-7-hyFc) on Day +60 after allogeneic hematopoietic cell transplantation. Dose assignment will follow a phase 1 dose-escalation design with dose levels of 240 μg/kg, 480 μg/kg, and 720 μg/kg.

Drugs: Efineptakin Alfa (rhIL-7-hyFc)

Sites

1 site in 1 country

  • Moffitt Cancer CenterTampa, Florida, United States